Mohanty Aditya, Vekariya Vasu, Yadav Shivani, Agrawal-Rajput Reena
Immunology Lab, Biotechnology & Bioengineering, Indian Institute of Advanced Research, Gandhinagar, Gujarat, 382426, India.
Immunology Lab, Biotechnology & Bioengineering, Indian Institute of Advanced Research, Gandhinagar, Gujarat, 382426, India.
Microb Pathog. 2025 Mar;200:107311. doi: 10.1016/j.micpath.2025.107311. Epub 2025 Jan 23.
Leishmaniasis is a tropical parasitic disease caused by the protozoan Leishmania which remains a significant global health concern with diverse clinical manifestations. Transmitted through the bite of an infected sandfly, its progression depends on the interplay between the host immune response and the parasite. The disease outcome is linked to macrophage polarisation into M1 and M2 phenotypes. M1 macrophages are pro-inflammatory and promote parasite clearance, while M2 macrophages support tissue repair and parasite survival by facilitating promastigote entry and intracellular amastigote proliferation.
The review focuses on discovering novel phytochemicals that exploit the immunomodulatory properties of macrophages, which can serve as an alternative antileishmanial treatments due to their diverse chemical structures and ability to modulate immune responses. It examines the immunomodulatory effects of phytochemicals that directly or indirectly promote antileishmanial activity by influencing macrophage polarisation and cytokine secretion. They can induce M1 macrophage polarisation to directly combat leishmaniasis or suppress M2 macrophages, thereby exerting indirect antileishmanial activity by influencing the release of M1-and M2-related cytokines.
RESULTS & DISCUSSION: Phytochemicals demonstrate antileishmanial effects through ROS production, M1 activation, and cytokine modulation. They regulate M1/M2-related cytokines and macrophage activity, influencing immune responses. Although their effects may be non-specific, targeted delivery strategies could overcome current therapeutic limitations, positioning phytochemicals as promising candidates for leishmaniasis treatment to counter the limitations of current medications.
利什曼病是一种由原生动物利什曼原虫引起的热带寄生虫病,仍然是一个严重的全球健康问题,具有多种临床表现。它通过受感染的白蛉叮咬传播,其病程取决于宿主免疫反应与寄生虫之间的相互作用。疾病的结果与巨噬细胞向M1和M2表型的极化有关。M1巨噬细胞具有促炎作用并促进寄生虫清除,而M2巨噬细胞则通过促进前鞭毛体进入和细胞内无鞭毛体增殖来支持组织修复和寄生虫存活。
本综述着重于发现利用巨噬细胞免疫调节特性的新型植物化学物质,由于其多样的化学结构和调节免疫反应的能力,可作为替代抗利什曼病的治疗方法。它研究了植物化学物质通过影响巨噬细胞极化和细胞因子分泌直接或间接促进抗利什曼病活性的免疫调节作用。它们可以诱导M1巨噬细胞极化以直接对抗利什曼病,或抑制M2巨噬细胞,从而通过影响与M1和M2相关的细胞因子的释放发挥间接抗利什曼病活性。
植物化学物质通过产生活性氧、激活M1和调节细胞因子来发挥抗利什曼病作用。它们调节与M1/M2相关的细胞因子和巨噬细胞活性,影响免疫反应。尽管它们的作用可能是非特异性的,但靶向递送策略可以克服当前的治疗局限性,使植物化学物质成为治疗利什曼病的有前途的候选药物,以应对当前药物的局限性。